Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: S&P Capital IQ Quantitative Report
$115.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Endologix Inc Reaffirms FY 2013 Guidance


Tuesday, 30 Jul 2013 04:16pm EDT 

Endologix Inc reiterated its fiscal 2013 financial guidance and anticipates revenue to be in the range of $128 million to $134 million, representing growth of 21% to 26% from fiscal 2012, Adjusted Net Loss Per Share (non-GAAP and defined below) of $(0.18) to $(0.22) per share, excluding the effect of increases or decreases in the Nellix contingent consideration and business development, Adjusted EBITDA (non-GAAP and defined below) of $(0.02) to $0.02 per share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $133 million, EPS of $(0.19) for fiscal 2013. 

Company Quote

12.6
0.29 +2.36%
21 Nov 2014